PBM
JSPR icon

Propel Bio Management’s Jasper Therapeutics JSPR Stock Holding History

Propel Bio Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,028,806
Closed -$2.45M – 23
2025
Q3 		$2.45M Buy
+1,028,806
New +$3.12M 2.45% 13
2025
Q1 		– Sell
-20,000
Closed -$428K – 21
2024
Q4 		$428K Buy
+20,000
New +$416K 0.42% 17

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Propel Bio Management's JSPR Position: Q4 2025 in Review

Propel Bio Management sold out of Jasper Therapeutics (JSPR) in Q4 2025, closing a stake of 1,028,806 shares — an estimated $2.45M sold.

Propel Bio Management first reported a position in JSPR in Q4 2024 and held it in 2 quarters. The position peaked at $2.45M in Q3 2025. 55 funds tracked by Wall St. Rank hold JSPR as of Q4 2025.

  • Propel Bio Management reported no remaining Jasper Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Propel Bio Management sold 1,028,806 Jasper Therapeutics shares in Q4 2025, an estimated $2.45M.
  • Propel Bio Management first reported a position in Jasper Therapeutics in Q4 2024 and held it in 2 quarters.
  • Propel Bio Management's Jasper Therapeutics position peaked at $2.45M in Q3 2025.
  • 55 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2025.

Based on Propel Bio Management's 13F filing for Q4 2025, filed 11 Feb 2026.